cllsociety.org/2015/05/asco...
Thanks to Dr Koffman at CLL Society for this bit of good news. Pretty durable response for such a tough crowd.
Jeff
BR + Idelalisib in RR. Data from ASCO and ASH ... - CLL Support
BR + Idelalisib in RR. Data from ASCO and ASH 2015
Written by
Justasheet1
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
AussieNeilPartnerAdministrator
Now updated for ASH:
ash.confex.com/ash/2015/web...
Check out the Kaplan Meyer curve (Fig 1) for the progression free survival comparison!
Neil
Not what you're looking for?
You may also like...
My Take on 3 Interesting Papers on CLL from ASCO 2015
Friends,
This week on CLL Society (http://cllsociety.org) in our 2015 conference coverage...
Reporting from ASCO 2019 (yes ASCO, not ASH)
Hi,
With ASH looming, it’s about time I finish up my reporting from ASCO 2019, the other huge...
ASH 2015: Dr. John M Pagel on the Problems with Idelalisib as Frontline Therapy in CLL
It has been a while since I posted an interview on my blog first instead of the CLL Society...
Part 2 of ASH Interview with Dr. Sharman, a patient meeting in Seattle and off to iwCLL later tonight
Friends,
This week on the CLL Society website, in our Conference coverage section, we share the...
CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO
Hi,
Just back from a frenetic and fantastic ASH, but still have news to share from ASCO.
But first...
Related Posts
- ASH 2013: Dr. John Pagel Speculates on the Future of CLL Therapies including the late breaking data on Idelalisib
- ASCO 2016: Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib in CLL
- ASCO 2014: Dr. Susan O'Brien Reviews the 3 years follow-up Data on Ibrutinib in CLL
ASH Conference Speaker: Diet valuable in reducing Inflammation and Symptom Burden in People with Blood Disorders
Expert Perspective on Key Trial Updates in Treatment of CLL: What You Need to Know From ASCO/EHA/ICML 2021
